These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 25229167)

  • 1. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
    Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
    Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
    Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
    HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
    Gantner P; Bani-Sadr F; Garraffo R; Roger PM; Treger M; Jovelin T; Pugliese P; Rey D;
    PLoS One; 2016; 11(10):e0164240. PubMed ID: 27798641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
    Cordery DV; Hesse K; Amin J; Cooper DA
    Antivir Ther; 2010; 15(7):1035-8. PubMed ID: 21041919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
    Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA
    J Acquir Immune Defic Syndr; 2012 Jun; 60(2):143-9. PubMed ID: 22421745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
    Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
    AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
    Fabbiani M; Di Giambenedetto S; Ragazzoni E; Colafigli M; Prosperi M; Cauda R; Navarra P; De Luca A
    HIV Med; 2010 May; 11(5):326-33. PubMed ID: 20070407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
    Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
    HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants.
    Gupta S; Lataillade M; Farber S; Kozal MJ
    J Int Assoc Physicians AIDS Care (Chic); 2009; 8(2):87-92. PubMed ID: 19270153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
    Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
    HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
    Rodríguez-Nóvoa S; Morello J; Barreiro P; Maida I; García-Gascó P; Vispo E; González-Pardo G; Parra A; Jiménez-Nácher I; Soriano V
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):821-5. PubMed ID: 18507524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
    Dejesus E; Mills A; Bhatti L; Conner C; Storfer S
    Int J Clin Pract; 2011 Dec; 65(12):1240-9. PubMed ID: 21999631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
    Castagna A; Galli L; Gianotti N; Torti C; Antinori A; Maserati R; d'Arminio Monforte A; Quiros-Roldan E; Salpietro S; Lazzarin A
    New Microbiol; 2013 Jul; 36(3):239-49. PubMed ID: 23912865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.